OakChart

Brainsway Ltd ADR

BWAYHealthcare·Medical Devices·Israel·Small·NASD·Nov 11 • 3:59 PM ET

11.24+0.57 (5.34%)
2026-11-11 22:59 CET
Market cap
429.50 USD m
Revenue, TTM
65.52 USD m
Net income, TTM
10.14 USD m
Free cash flow, TTM
12.93 USD m
EPS diluted, TTM
0.25
P/E
45.73
Compare

Price

BWAY against its 20, 50 and 200-day averages
2050200earnings
10.0012.0014.0016.00311K623KVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26BWAYclose 11.2420-day 11.4150-day 12.43200-day 13.8911.2452w high

35.4% under the 52-week high of 17.40 on 12 Aug 2026. 52-week low 7.14 on 21 Nov 2025. Last 15 sessions, 20.0% high to low

Volume 1.36× normal · the line is the 50-bar volume average

Profile

BWAY
52-week range, 40% of the way up
7.1417.40

Brainsway Ltd. engages in the development and sale of non-invasive neurostimulation treatments using the proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) technology for the treatment of major depressive disorder (MDD) and obsessive-compulsive disorder (OCD). The Deep TMS uses magnetic pulses to stimulate neurons and consequently modulates the physiological activity of the brain. The company was founded by Avner Hagai, Yiftach Roth, Abraham Zangen, and David Zacut in 2003 and is headquartered in Jerusalem, Israel.

Employees129
IPOApr 17, 2019
Beta1.36
ATR, 14d0.68
Rel volume1.36
Short float0.67%
Insider own26.41%
Inst own15.95%

Snapshot

6 groups

Valuation

Index-
Market Cap452.41M
Enterprise Value395.86M
Income10.14M
Sales65.52M
Book/sh2.04
Cash/sh1.58
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout0.00%
Employees129
IPOApr 17, 2019

Ratios

P/E45.73
Forward P/E22.53
PEG0.52
P/S6.90
P/B5.50
P/C7.13
P/FCF34.99
EV/EBITDA37.10
EV/Sales6.04
Quick Ratio2.62
Current Ratio2.89
Debt/Eq0.08
LT Debt/Eq0.07
Option/ShortYes / Yes

Earnings

EPS (ttm)0.25
EPS next Y0.50
EPS next Q0.09
EPS this Y64.24%
EPS next Y68.72%
EPS next 5Y43.49%
EPS past 3/5Y- -
Sales past 3/5Y24.82% 18.84%
EPS Y/Y TTM65.86%
Sales Y/Y TTM32.47%
EPS Q/Q19.81%
Sales Q/Q32.56%
EarningsNov 10 BMO
EPS/Sales Surpr.-42.33% 1.96%

Ownership

Insider Own26.41%
Insider Trans0.00%
Inst Own15.95%
Inst Trans0.53%
ROA8.48%
ROE13.31%
ROIC11.53%
Gross Margin76.06%
Oper. Margin13.63%
Profit Margin15.47%
SMA20-1.49%
SMA50-9.55%
SMA200-19.09%
Trades-

Technical

Shs Outstand40.25M
Shs Float29.62M
Short Float0.67%
Short Ratio1.76
Short Interest0.20M
52W High17.40 -35.40%
52W Low7.14 57.53%
Volatility6.29% 4.30%
ATR (14)0.68
RSI (14)45.94
Beta1.36
Rel Volume1.36
Avg Volume113.04K
Volume153,277

Performance

Perf Week0.27%
Perf Month-5.70%
Perf Quarter-31.75%
Perf Half Y-31.09%
Perf YTD18.19%
Perf Year48.09%
Perf 3Y477.89%
Perf 5Y181.35%
Perf 10Y-
Recom1.00
Target Price19.27
Prev Close10.67
Price11.24
Change %5.34%

Analyst ratings

latest 9 of 9
DateActionAnalystRating changeTargetImplied
Jul 20, 2026InitiatedBBTIG ResearchBuy$18+60.1%
Nov 16, 2023DowngradeRRaymond JamesOutperform → Mkt Perform
Mar 03, 2022InitiatedLLoop CapitalBuy$15+33.5%
Jul 19, 2021InitiatedHH.C. WainwrightBuy$17+51.2%
Apr 20, 2021InitiatedNNorthland CapitalOutperform$15+33.5%
May 13, 2019InitiatedRRaymond JamesOutperform$14+24.6%
May 13, 2019InitiatedOOppenheimerOutperform
May 13, 2019InitiatedLLadenburg ThalmannBuy
May 13, 2019InitiatedCCantor FitzgeraldOverweight$17+51.2%

Peers

Mkt cap
TickerCompanyMkt cap
STIMNeuronetics Inc125.92M
LIVNLivaNova PLC5.01B
NPCENeuroPace Inc429.73M
ECORElectroCore Inc71.13M
MDTMedtronic Plc129.98B
NXLNexalin Technology Inc1.83M
CLPTClearPoint Neuro Inc293.94M
INSPInspire Medical Systems Inc1.80B
BSXBoston Scientific Corp65.41B
CMPSCompass Pathways Plc ADR1.32B

Held by

AUM
TickerCompanyAUM
IZRLARK Israel Innovative Technology ETFAUM: 118.95M
ITEQAmplify BlueStar Israel Technology ETFAUM: 97.54M
APIEActivePassive International Equity ETFAUM: 1.13B
EHLSEven Herd Long Short ETFAUM: 53.35M
IBRNiShares Neuroscience and Healthcare ETFAUM: 8.68M
ASDDefiance Autism Impact ETFAUM: 1.39M

News

latest 14 of 200
  • BrainsWay Misses On EPS, But Margin Expansion And A Swelling Backlog Make The Shortfall Look Like Noise In A Stock Priced For Trouble (Earnings Whispers) -8.33%
  • BrainsWay Reports Third Quarter 2026 Financial Results and Operational Highlights (GlobeNewswire)
  • BrainsWay's Q3 Test: Can Record Growth Win Back A Stock Down 30%? (Earnings Whispers)
  • BrainsWay Announces Strategic Collaboration with Mindful Health Solutions (GlobeNewswire)
  • BrainsWay to Report Third Quarter 2026 Financial Results on November 10, 2026 (GlobeNewswire)
  • BrainsWay Expands U.S. Insurance Coverage for Deep TMS Treatment of OCD to Over 118 Million Lives (GlobeNewswire)
  • BrainsWay Announces Strategic Collaboration with Inland Psychiatry Medical Group (GlobeNewswire)
  • BrainsWay Reports Rise in Favorable Accelerated Deep TMS Coverage to Over 70 Million Covered Lives (GlobeNewswire)
  • BrainsWay Reports Promising Pilot Study Results in Patients with Depression and Comorbid Early-Stage Alzheimer's Disease Treated with Deep TMS (GlobeNewswire)
  • BrainsWay Deep TMS Study Shows 70% Reduction in Patients Experiencing Suicidal Ideation (GlobeNewswire)
  • BrainsWay Ltd (BRSYF) (Q2 2026) Earnings Call Highlights: Revenue Surges 35% to $17. ... (GuruFocus.com) +10.81%
  • BrainsWay Reports Second Quarter 2026 Financial Results and Operational Highlights (GlobeNewswire)
  • Earnings To Watch: BrainsWay Ltd (BWAY) Q2 2026 -- GF Value Sees 35% Downside (GuruFocus.com)
  • BrainsWay to Report Second Quarter 2026 Financial Results on August 12, 2026 (GlobeNewswire) -8.59%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-100.0500.0870.05018.1517.803
2026Q22026-08-120.0700.0730.06917.1116.543
2026Q12026-05-130.0300.0300.05715.5314.633
2025Q42026-03-110.0700.0310.07014.5514.023
2025Q32025-11-110.0200.0230.04113.5113.033
2025Q22025-08-130.0250.0160.05512.6312.344
2025Q12025-05-130.0100.0110.02011.5411.454
2024Q42025-03-110.0200.0110.04211.4110.884
2024Q32024-11-120.0100.0050.02010.5010.084
2024Q22024-08-060.010-0.0010.01810.019.534
2024Q12024-05-080.000-0.0080.0039.108.724
2023Q42024-03-060.000-0.0070.0049.038.654
2023Q32023-11-15-0.005-0.022-0.0078.307.745
2023Q22023-08-09-0.025-0.042-0.0507.837.085
2023Q12023-05-17-0.035-0.054-0.0736.636.405
2022Q42023-03-15-0.060-0.063-0.1176.036.306

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2018FY-0.194--0.38816.29-
2019FY-0.250-0.261-0.50523.1022.97
2020FY-0.120-0.135-0.24222.0621.96
2021FY-0.105-0.129-0.20829.6629.52
2022FY-0.200-0.205-0.40327.1827.42
2023FY-0.065-0.071-0.12631.7931.33
2024FY0.0450.0310.05641.0240.45
2025FY0.1800.115-0.39052.2351.68
2026FY-0.296--69.78
2027FY-0.499--85.84
2028FY-0.532--101.72

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-1031018.9518.8019.16
2026Q4S2026-11-0230018.7318.5018.88
2026Q4S2026-10-2630018.7418.5018.90
2026Q4S2026-10-1632018.7418.5018.90
2026Q4S2026-10-1532018.7318.5018.88
2026Q4S2026-10-0932018.7318.5018.88
2026Q4S2026-09-0832018.7318.5018.88
2026Q4S2026-09-0732018.7418.5018.90
2026Q4S2026-08-2832018.7318.4818.90
2026Q4S2026-08-1232018.7018.4818.82
2026Q4S2026-08-0531018.1917.6718.80
2026Q4S2026-07-2731118.1917.6718.80
2026Q4S2026-07-2331218.1917.6718.80
2026Q4S2026-07-1731218.1917.6718.80

Estimate history

EPS, annual-0.484-0.388-0.505-0.242-0.208-0.403-0.1260.0560.1840.2458
Period201720182019202020212022202320242025TTM
EPS, quarterly0.020.0420.020.0550.0410.070.0570.0690.05
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual10.75316.34423.17622.21229.67827.07131.70341.21152.63965.52
Period201720182019202020212022202320242025TTM
Sales, quarterly10.53311.50511.47612.90313.57614.63615.48917.40117.996
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual16.6416.6422.23622.25132.91133.05333.24237.62639.16640.253
Period201720182019202020212022202320242025MRQ
Shares, quarterly33.35837.62637.73837.7938.00739.16640.03340.12940.253
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue65.5252.6441.2131.7027.0729.6822.2123.1816.34
Cost of Goods Sold Incl. D&A15.6913.6211.098.676.705.824.535.273.64
Gross Profit49.8339.0230.1223.0320.3723.8617.6917.9112.71
Selling, General and Administrative Excl. Other40.9134.6728.7327.9532.1827.4621.2726.4117.80
Research and Development12.209.407.026.517.546.195.567.866.11
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income8.934.361.40-4.91-11.81-3.61-3.58-8.50-5.10
Interest Expense2.380.650.240.300.070.140.110.510.39
Unusual Expense0.00-2.61-1.110.000.80-0.031.03-0.060.03
Net Income Before Taxes10.077.773.48-3.94-12.98-6.42-5.18-9.94-6.25
Income Taxes-0.070.140.540.250.310.040.240.420.21
Consolidated Net Income10.147.642.93-4.19-13.30-6.47-5.42-10.36-6.46
Net Income From Continuing Operations10.147.642.93-4.19-13.30-6.47-5.42-10.36-6.46
Net Income10.147.642.93-4.19-13.30-6.47-5.42-10.36-6.46
EPS (Recurring)-0.140.03-0.13-0.39-0.21-0.21-0.51-0.39
EPS (Basic, Before Extraordinaries)0.250.200.09-0.13-0.40-0.21-0.24-0.51-0.39
EPS (Diluted)0.250.180.06-0.13-0.40-0.21-0.24-0.51-0.39
EBITDA10.675.913.18-3.58-10.28-1.92-1.95-5.70-3.87
Non-Operating Income (Expense)3.521.451.201.28-0.30-2.71-0.47-0.99-0.73
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense-0.931.100.281.125.310.610.980.54
Price To Earnings Ratio44.2744.2757.01------
Price To Sales Ratio8.957.163.983.391.504.043.814.31-
Gross Margin76.0674.1373.1072.6575.2680.3879.6277.2877.74
Operating Margin13.638.283.39-15.50-43.63-12.15-16.12-36.69-31.19
Net Margin15.4714.507.12-13.20-49.12-21.79-24.41-44.71-39.51
Shares Outstanding40.2539.1737.6333.2433.0532.9122.2522.2416.64
Market Capitalization429.50429.50177.41107.5640.78126.7183.88108.40108.40

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue18.0017.4015.4914.6413.5812.9011.4811.50
Cost of Goods Sold Incl. D&A3.984.423.853.453.373.202.912.93
Gross Profit14.0212.9911.6411.1910.219.708.578.58
Selling, General and Administrative Excl. Other11.4510.559.649.268.959.117.998.14
Research and Development3.503.272.872.552.412.392.322.06
Other Operating Expense0.000.000.000.000.000.000.00-
Operating Income2.572.432.001.931.260.590.570.43
Interest Expense0.730.890.320.430.570.630.580.34
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes2.142.972.402.561.822.141.261.75
Income Taxes-0.060.210.12-0.340.240.070.160.19
Consolidated Net Income2.202.762.282.891.572.071.101.56
Net Income From Continuing Operations2.202.762.282.891.572.071.101.56
Net Income2.202.762.282.891.572.071.101.56
EPS (Recurring)0.050.070.06-0.040.05-0.04
EPS (Basic, Before Extraordinaries)0.050.070.060.070.040.050.030.04
EPS (Diluted)0.050.070.060.070.040.050.020.04
EBITDA3.042.882.462.281.660.990.961.15
Non-Operating Income (Expense)0.311.430.721.061.132.191.271.65
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.62-0.26-----
Price To Earnings Ratio44.2768.3064.5547.7445.1745.2543.6457.01
Price To Sales Ratio8.9510.199.407.085.795.354.114.31
Gross Margin77.9074.6275.1776.4475.1975.2074.6474.57
Operating Margin14.2713.9812.9113.179.274.584.993.78
Net Margin12.2515.8414.7419.7611.5916.059.6013.56
Shares Outstanding40.2540.1340.0339.1738.0137.7937.7437.63
Market Capitalization429.50622.41532.04372.47286.38248.47178.69177.41

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments69.3869.6246.2647.8557.3517.1821.909.0714.56
Short Term Receivables4.114.603.784.846.337.126.264.093.31
Inventories6.524.433.723.840.000.000.000.000.00
Other Current Assets3.811.031.711.561.770.000.670.320.02
Total Current Assets83.8279.6755.4758.0965.4524.3028.8313.4817.89
Net Property, Plant & Equipment12.7811.955.795.359.339.559.747.637.09
Total Investments and Advances14.660.000.000.000.000.160.001.012.01
Intangible Assets-----0.000.000.000.02
Other Assets1.932.701.721.040.950.000.171.490.03
Total Assets113.1994.3262.9764.4875.7334.0138.7423.6027.03
Short Term Debt Incl. Current Port. of LT Debt1.070.820.230.230.500.430.410.750.00
Accounts Payable2.432.870.761.121.100.781.322.241.63
Income Tax Payable0.010.270.500.000.020.000.000.130.13
Other Current Liabilities18.9811.398.276.797.455.594.985.224.37
Total Current Liabilities22.4915.359.768.149.076.806.728.346.13
Long Term Debt5.744.800.240.250.250.240.002.082.73
Provision for Risks Charges0.000.000.000.000.000.000.000.00-
Other Liabilities6.766.055.314.673.171.812.431.250.42
Total Liabilities35.0026.2015.3113.0612.498.859.1511.679.28
Non-Equity Reserves5.035.806.086.025.925.525.374.985.03
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity73.1662.3141.5845.4057.3319.6324.226.9512.72
Total Shareholders Equity73.1662.3141.5845.4057.3319.6324.226.9512.72
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity73.1662.3141.5845.4057.3319.6324.226.9512.72
Total Liabilities & Stockholders Equity113.1994.3262.9764.4875.7334.0138.7423.6027.03
Book Value Per Share1.871.661.251.371.740.881.090.420.76
Tangible Book Value Per Share1.871.661.251.371.740.881.090.420.76
Full-Time Employees1291201061341181001079679
Price to Book Ratio5.412.852.610.832.214.274.484.13-
Return on Assets7.363.73-6.57-18.97-11.78-14.91-33.24-25.51-30.25
Return on Equity11.275.65-9.63-25.89-16.80-24.73-66.48-65.65-61.79
Return on Invested Capital9.684.37-10.01-29.13-11.23-27.28-42.78-71.48-46.02
Quick Ratio3.444.905.306.667.223.574.291.622.92
Current Ratio3.735.195.687.147.223.574.291.622.92

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income10.207.642.93-4.19-13.30-6.47-5.42-10.36-6.46
Depreciation1.741.551.781.331.531.691.632.801.22
Other Funds (Non Cash)2.450.223.232.503.504.602.172.451.68
Funds from Operations14.389.407.95-0.35-8.27-0.18-1.63-5.11-3.56
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-1.458.232.401.63-1.451.070.18-2.16-0.20
Cash from Operating Activities12.9317.6310.351.28-9.720.88-1.45-7.27-3.76
Capital Expenditures0.52-3.02-4.79-2.40-0.02-2.24-2.49-3.32-1.97
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.001.930.000.000.000.00
Purchase or Sale of Investments-51.39-14.6135.17-34.9140.10-40.010.010.870.95
Purchase of Investments-51.40-14.630.00-34.91--40.03--0.12-0.05
Sale Or Maturity of Investments0.010.0235.17-40.100.020.010.991.00
Other Uses0.000.000.000.000.000.000.000.00-0.12
Other Sources0.020.020.08-0.000.000.000.000.00
Cash from Investing Activities-50.22-17.6030.45-37.3142.00-42.25-2.48-2.45-1.13
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock0.000.0019.890.00-0.0542.290.0026.420.00
Repurchase of Common Pref Stock0.000.000.000.00-0.050.000.000.000.00
Sale of Common Pref Stock0.000.0019.890.000.0042.290.0026.420.00
Proceedsfrom Stock Options0.000.0016.430.000.0042.290.0026.420.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.000.00-3.010.00
Change in Long Term Debt0.000.000.000.000.000.000.00--
Issuance of Long Term Debt0.000.000.000.000.000.000.00--
Reduction of Long Term Debt-0.000.000.000.000.000.00--
Net Financing Active Other Cash Flow-2.36-0.88-1.11-0.75-0.96-0.27-0.62-0.43-0.26
Other Financing Activities Uses-2.36-1.21-1.11-0.78-0.97-0.76-0.66-0.60-0.41
Cash from Financing Activities-3.10-1.7218.35-1.02-1.5441.54-1.0422.55-0.26
Exchange Rate Effect-0.110.04-0.050.09-0.20-0.220.22-0.08-0.37
Net Change in Cash-40.50-1.6659.10-36.9730.54-0.04-4.7512.75-5.52
Free Cash Flow12.9315.276.53-1.10--1.35-3.93-10.59-5.73
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Price to Free Cash Flow45.3724.6725.09------
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments63.4362.3658.8969.3870.7178.25
Short Term Receivables6.627.037.534.115.133.87
Inventories7.677.317.086.524.424.19
Other Current Assets3.764.725.133.812.682.72
Total Current Assets81.4881.4278.6383.8282.9389.03
Net Property, Plant & Equipment12.9613.3912.9112.7814.0213.17
Total Investments and Advances28.8825.0023.1614.6612.575.46
Other Assets2.582.162.311.933.553.90
Total Assets125.89121.97117.00113.19113.06111.57
Short Term Debt Incl. Current Port. of LT Debt1.231.241.111.071.040.91
Accounts Payable2.172.502.932.432.791.21
Income Tax Payable---0.01--
Other Current Liabilities24.7618.9319.5218.9822.1623.39
Total Current Liabilities28.1622.6723.5622.4925.9925.51
Long Term Debt5.655.895.605.745.715.22
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities6.349.837.846.766.477.10
Total Liabilities40.1538.3937.0035.0038.1737.83
Non-Equity Reserves3.514.394.205.034.835.60
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity82.2479.1975.8073.1670.0768.13
Total Shareholders Equity82.2479.1975.8073.1670.0768.13
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity82.2479.1975.8073.1670.0768.13
Total Liabilities & Stockholders Equity125.89121.97117.00113.19113.06111.57
Book Value Per Share2.041.971.891.871.841.80
Tangible Book Value Per Share2.041.971.891.871.841.80
Full-Time Employees---129--
Price to Book Ratio5.418.197.215.094.093.65
Return on Assets8.488.148.127.366.816.09
Return on Equity13.3112.9012.6411.2711.059.71
Return on Invested Capital2.513.242.813.672.082.82
Quick Ratio2.623.273.043.443.023.33
Current Ratio2.893.593.343.733.193.49

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income2.202.752.282.961.582.05
Depreciation0.470.450.460.360.410.39
Other Funds (Non Cash)1.230.940.170.111.37-1.02
Funds from Operations3.904.142.923.423.351.42
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital2.252.22-1.75-4.17-1.9711.10
Cash from Operating Activities6.166.361.17-0.751.3812.52
Capital Expenditures0.39-0.84-0.831.79-1.34-1.82
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments-37.51-1.91-8.47-3.502.73-14.20
Purchase of Investments-37.52-1.90-8.48-3.502.73-14.20
Sale Or Maturity of Investments0.01-0.000.000.00-0.00-
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.020.000.00
Cash from Investing Activities-37.12-2.74-9.30-1.051.39-16.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.000.000.000.000.000.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.000.000.000.000.000.00
Proceedsfrom Stock Options0.000.000.000.000.000.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt--0.000.000.00-
Net Financing Active Other Cash Flow-0.88-0.00-0.73-0.750.00-0.01
Other Financing Activities Uses-0.88-0.00-0.73-0.750.00-0.01
Cash from Financing Activities-1.04-0.16-0.90-1.00-0.21-0.27
Exchange Rate Effect-0.09-0.03-0.010.020.000.05
Net Change in Cash-32.103.42-9.04-2.782.57-3.70
Free Cash Flow6.555.460.400.520.5811.34
Price to Free Cash Flow45.3789.4241.4522.7115.5213.18

Revenue breakdown

Surgical & Medical Instruments & Apparatus2024: 41.02M 2025: 52.23M
Country Of U S A2024: 33.23M
Israel2025: 52.23M
Other2024: 7.79M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-300.67%0.2M29.6M108.16K
2026-10-150.76%0.2M29.6M122.39K
2026-09-300.85%0.3M29.6M115.52K
2026-09-150.67%0.2M29.6M116.68K
2026-08-310.70%0.2M29.5M119.78K
2026-08-140.53%0.2M29.5M129.24K
2026-07-310.40%0.1M29.5M130.05K
2026-07-150.58%0.2M29.5M118.83K
2026-06-300.62%0.2M29.5M134.62K
2026-06-150.42%0.1M29.5M147.47K
2026-05-290.46%0.1M29.4M165.86K
2026-05-150.45%0.1M29.4M173.21K
2026-04-300.41%0.1M29.4M171.77K
2026-04-150.34%0.1M29.4M190.03K
2026-03-310.29%0.1M34.6M210.67K
2026-03-130.34%0.1M34.6M206.38K
2026-02-270.60%0.2M33.9M191.21K
2026-02-130.30%0.1M33.9M179.40K
2026-01-300.52%0.2M33.9M180.24K
2026-01-150.77%0.3M33.9M169.69K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.506.5010.900.0023.4440.000.000.959-0.1020.002
call5.004.008.400.0010.8170.000.000.904-0.1100.003
call7.501.705.900.005.9460.000.000.833-0.0990.004
call10.000.004.102.105.37710.000.000.699-0.0730.006
call12.500.002.000.503.6971.000.000.529-0.1420.007
call15.000.003.400.004.4980.000.000.476-0.1780.007
call17.500.003.400.005.2010.000.000.444-0.2040.007
call20.000.003.400.005.8080.000.000.424-0.2210.007
call22.500.003.400.006.2630.000.000.409-0.2360.007
call25.000.003.400.006.6510.000.000.398-0.2490.007
put2.500.003.400.0011.4740.000.00-0.042-0.1000.002
put5.000.003.400.006.5250.000.00-0.096-0.1090.003
put7.500.003.400.003.9720.000.00-0.167-0.0980.004
put10.000.000.850.001.9850.000.00-0.323-0.0730.006
put12.500.004.604.105.5262.000.00-0.466-0.1380.007
put15.001.656.100.004.8650.000.00-0.524-0.1760.007
put17.504.108.500.005.5720.000.00-0.556-0.2020.007
put20.006.6011.000.006.1350.000.00-0.577-0.2210.007
put22.509.1013.500.006.6020.000.00-0.592-0.2370.007
put25.0011.6016.000.007.0000.000.00-0.603-0.2500.007

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-106-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-11-10SEC
2026-11-106-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-11-10SEC
2026-11-026-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-11-02SEC
2026-10-266-K/A2026-10-26SEC
2026-10-266-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-26SEC
2026-10-216-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-11-25SEC
2026-10-196-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-19SEC
2026-10-136-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-13SEC
2026-09-296-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-30SEC
2026-09-086-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-08SEC
2026-08-276-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-27SEC
2026-08-126-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-12SEC
2026-08-126-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-12SEC
2026-07-29SCHEDULE 13G/ASEC
2026-07-206-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-07-20SEC
2026-07-166-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-07-16SEC
2026-06-296-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-29SEC
2026-06-224Statement of changes in beneficial ownership of securities2026-05-25SEC
2026-06-226-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-22SEC
2026-06-096-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-09SEC
2026-06-03SCHEDULE 13G/ASEC
2026-06-034Statement of changes in beneficial ownership of securities2026-06-01SEC
2026-05-264Statement of changes in beneficial ownership of securities2026-05-25SEC
2026-05-214Statement of changes in beneficial ownership of securities2026-05-19SEC
2026-05-186-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-05-18SEC
2026-05-136-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-05-13SEC
2026-05-136-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-05-13SEC
2026-05-13SCHEDULE 13G/ASEC
2026-05-05SCHEDULE 13G/ASEC
2026-04-20S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
Valor Management LLC13.24%
MASTERS CAPITAL MANAGEMENT LLC3.74%
ACADIAN ASSET MANAGEMENT LLC1.91%
ESSEX INVESTMENT MANAGEMENT CO LLC1.43%
RENAISSANCE TECHNOLOGIES LLC1.19%
Cresset Asset Management, LLC0.78%
HWG Holdings LP0.63%
Y.D. More Investments Ltd0.56%
MORGAN STANLEY0.47%
EAGLE GLOBAL ADVISORS LLC0.45%

Funds

Fund% owned
MEDIUM-DURATION BOND FUND5.73%
Empower Core Bond Fund0.98%
Timothy Plan Israel Common Values Fund0.46%
ARK Israel Innovative Technology ETF0.37%
1290 Essex Small Cap Growth Fund0.35%
Royce Smaller-Companies Growth Fund0.24%
Amplify BlueStar Israel Technology ETF0.19%
Old Westbury Small & Mid Cap Strategies Fund0.13%
Steward Values Enhanced International Fund0.06%
ActivePassive International Equity ETF0.04%

OakChart. BWAY. Cached 15 minutes.

Some panels did not load: insider.